Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Points - The CoreWeave class action lawsuit has been initiated against CoreWeave, Inc. and its executives for alleged violations of the Securities Exchange Act of 1934 during the class period from March 28, 2025, to December 15, 2025 [1][3] - CoreWeave is accused of overstating its ability to meet customer demand and failing to disclose significant risks associated with its reliance on a single third-party data center supplier [3][4] - The lawsuit highlights a significant deal worth up to $11.9 billion with OpenAI announced shortly before CoreWeave's IPO, and a subsequent all-stock acquisition agreement with Core Scientific, which was later terminated due to insufficient shareholder votes [2][4] Allegations and Impact - Allegations include that CoreWeave's executives made misleading statements regarding the company's operational capabilities and the risks posed by its data center supplier, which were likely to negatively impact revenue [3][5] - Following the announcement of lower revenue guidance due to delays from a third-party data center developer, CoreWeave's stock price fell by over 16% [5] - A Wall Street Journal article revealed that delays were more severe than previously acknowledged, leading to an additional 3.4% drop in CoreWeave's stock price [6] Legal Process - Investors who purchased CoreWeave securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [7][8] - The lead plaintiff can select a law firm to litigate the case, and participation as lead plaintiff is not required to share in any potential recovery [8] About the Law Firm - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [9]

Core Points - A securities fraud class action lawsuit has been filed against CoreWeave, Inc. for alleged misstatements and omissions regarding its financial performance and operational risks during the Class Period from March 28, 2025, to December 15, 2025 [1][6] - The lawsuit claims that CoreWeave overstated its ability to meet customer demand and failed to adequately disclose risks associated with reliance on a single third-party data center supplier, which could negatively impact revenue [2] Company Information - CoreWeave, Inc. is publicly traded on NASDAQ under the ticker CRWV and is currently facing legal challenges due to allegations of securities fraud [1][6] - The law firm Kessler Topaz Meltzer & Check, LLP is representing affected investors and has a history of handling significant securities litigation cases [5][7] Legal Process - Investors who suffered losses can seek to be appointed as lead plaintiffs by March 13, 2026, which allows them to represent the class in the lawsuit [3][4] - The firm encourages affected investors to contact them for more information regarding the lawsuit and potential recovery of losses [4][6]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Bath & Body Works, Inc. for alleged material misstatements and omissions during the class period from June 4, 2024, to November 19, 2025, affecting investors who purchased or acquired the company's securities [1][6]. Summary by Relevant Sections Allegations - The complaint claims that Bath & Body Works made materially false and misleading statements and failed to disclose adverse facts about its business and operations [2]. - Specific allegations include the failure of the company's strategy of pursuing "adjacencies, collaborations and promotions" to grow its customer base and net sales [2]. - It is alleged that the company relied on brand collaborations to mask weak financial results and was unlikely to meet its previously issued financial guidance [2]. Legal Process - Investors affected by the alleged fraud can seek to be appointed as lead plaintiffs by March 13, 2026, through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - The lead plaintiff will represent the class in directing the litigation and selecting counsel, with the ability to share in any recovery not affected by the decision to serve as lead plaintiff [3]. Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and investor protection, representing both individual and institutional investors [5][7]. - The firm has a history of leading significant recoveries in securities litigation and has received numerous accolades for its work [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Bath & Body Works is a specialty retailer focused on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. Financial Performance - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 financial results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53 per diluted share, leading to a stock price drop of $2.18, or 6.9%, from $31.54 to $29.36 per share [6]. - Following the release of Q3 2025 financial results on November 20, 2025, the company announced further cuts to its full-year guidance and acknowledged that its strategy of pursuing adjacencies had not grown its total customer base, resulting in a stock price decline of $5.22, or 24.8%, from $21.04 to $15.82 per share [7]. Legal Context - Investors have until March 16, 2026, to request to be appointed to lead the class action case, which is pending in the U.S. District Court for the Southern District of Ohio, under the caption Lingam v. Bath & Body Works, Inc., et al. [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Bath & Body Works securities [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decrease of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Core Viewpoint - A securities class action lawsuit has been filed against Ardent Health, Inc. for failing to disclose material information during the class period, leading to significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who suffered substantial losses from purchasing Ardent's securities between July 18, 2024, and November 12, 2025, have until March 9, 2026, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Middle District of Tennessee [1]. Group 2: Financial Impact - On November 12, 2025, Ardent disclosed a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability and recent evaluations of historical collection trends [4]. - The company cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Ardent also recorded a $54 million increase in professional liability reserves related to recent settlements and ongoing litigation [4]. - Following this news, Ardent's share price fell by $4.75, or nearly 34%, from $14.05 to $9.30 per share on November 13, 2025, with unusually heavy trading volume [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case [5]. - The firm has been recognized among the top 10 firms nationally based on total settlement value and serves a variety of clients seeking recoveries for investment losses due to corporate fraud [5].

Core Viewpoint - A securities class action lawsuit has been filed against Bitdeer Technologies Group for failing to disclose material information, leading to significant investor losses during the specified Class Period from June 6, 2024, to November 10, 2025 [1][3]. Group 1: Lawsuit Details - Investors who suffered substantial losses have until February 2, 2026, to file lead plaintiff applications in the lawsuit against Bitdeer [1][2]. - The lawsuit is pending in the United States District Court for the Southern District of New York, under the case name Ismail N. Sakar v. Bitdeer Technologies Group, et al., No. 25-cv-10069 [5]. Group 2: Financial Performance - On November 10, 2025, Bitdeer reported a net loss of $266.7 million, or $1.28 per share, attributed to increased operating expenses related to research and development of its ASICs roadmap [4]. - Following the announcement of these financial results, Bitdeer's share price dropped from $17.65 to $15.02, marking a decline of over 14% [4]. Group 3: Company Background - Bitdeer Technologies Group is involved in the cryptocurrency sector, specifically focusing on Bitcoin mining technology [4]. - Kahn Swick & Foti, LLC, the law firm representing the investors, is recognized as one of the top boutique securities litigation firms in the United States, serving both institutional and retail investors [5].